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 “All of the fruits of the tremendous explosion in innovation that’s been occurring in biomedical research – 
which make the molecular metamorphosis possible – fulfill their purpose only when they are translated into 
interventions and solutions that are applied to patients.” 
—Dr. Andrew von Eschenbach, U.S. Food and Drug Administration Commissioner, 2006 
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Introduction 
More than a decade after the 
successful mapping of the human 
genome, clinical genomics1 is 
starting to permeate important parts 
of patient care and propel ripples 
throughout the entire U.S. health care 
system.  
Although the field has fallen far short 
of the transformational therapeutic 
impact once widely predicted, 
particularly in regard to common 
diseases, specific interventions have 
crossed the divide between rarity and 
regular use. Genetic testing routinely 
guides therapy in several common 
cancers and in HIV disease, and use 
of costly molecularly targeted anti-
cancer drugs is rising sharply. Six in 
10 primary care physicians have 
ordered a genetic test.2  
Pharmacogenomics, the science of 
how genetic differences can affect 
individual drug responses, has 
become an established part of drug 
discovery and of the guidance given 
to physicians on the labels of drugs 
approved by the Food and Drug 
Administration (FDA).  
Yet while increased adoption is 
partly due to growing acceptance of 
useful interventions, it is also due to 
a porous regulatory structure that 
allows diagnostic tests of unproven 
or no value to be marketed to 
providers and patients. The result of 
this policy vacuum is a disturbing 
paradox. Genomics as a field is 
beginning to demonstrate its 
profound potential to improve health 
and health care. At the same time, the 
evidence suggests that the current use 
of clinical genomics tests and 
therapies often contributes to 
wasteful spending and even patient 
harm. 
A 2008 article in Health Affairs 
warned that the low threshold for 
allowing “unsubstantiated [genomic] 
technologies to enter into practice 
[has] the potential to overwhelm the 
health system.”3 Since then, private-
sector efforts to encourage use of 
clinical genomics have intensified, 
while efforts to ensure appropriate 
use have lagged. Evidence-based 
guidelines for clinicians remain 
scarce, despite growing efforts to 
address the problem, and those that 
do exist can be contradictory. A 
federal advisory committee that 
pushed for greater regulation and 
more reliable data had little impact 
and was disbanded last year. 
Meanwhile, government funding for 
assessment of the evidence on 
genomic interventions has plunged. 
Integrating clinical genomics into 
routine care poses multiple system 
challenges beyond the direct doctor-
patient interaction. Health 
information technology systems 
typically possess neither the ability to 
present genomic information in a 
structured way clinicians can use nor 
the large data storage capabilities 
such information demands. 
Comparative effectiveness research 
needs to focus on identifiable 
subpopulations where clinical 
genomics interventions can have the 
most powerful impact, but the 
concept of “identifiable” can raise 
awkward questions about race and 
ethnicity.  
Finally, the science involved is 
complicated and often confusing to 
patients, payers, providers and 
policymakers alike, making informed 
decisions that much more difficult.  
Controversies over appropriate 
genetic testing related to the risk of 
breast cancer have already drawn in 
all three branches of the federal 
government and numerous private 
players. As issues related to clinical 
genomics become a regular part of 
access, cost and quality discussions, 
it is time for a policy community 
long fluent in the argot of DRGs and 
billing codes to acquire similar 
proficiency in the language of DNA 
and genetic codes. This paper aims to 
assist that process by examining what
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Language shapes perceptions, but not always accurately. Proponents of 
“personalized” and “predictive” medicine tend to use those terms within a 
framework of DNA determinism that pays little more than lip service to individual 
characteristics unrelated to genetic biomarkers. Yet 40 percent of the factors 
contributing to premature death among Americans are linked to behavior, 30 
percent to genetics, 15 percent to social factors, 10 percent to medical care and 5 
percent to environment.1 A personal genotype remains a much less powerful 
predictor of future health than a good family history. 
As genomic medicine enters the health care mainstream, those in the field should 
consider a description of their role that recognizes the importance of other 
approaches. Terms such as “genetically personalized medicine” or “personalized 
genetic medicine” would make policy discussions about “precision medicine” a 
great deal more precise. 
_____________ 
1McGinnis JM, Williams-Russo P and Knickman JR. “The Case For More Active Policy 
Attention To Health Promotion.” Health Affairs, 21(2): 78–93, 2002. 
is hype, what is hopeful and what is 
starting to make a genuine difference 
in clinical genomics. It also makes 
specific recommendations about the 
type of information that would help 
policymakers, payers, providers and 
the public make better decisions 
about the use of clinical genomics.  
The Beginning of the 
Bench-to-Bedside Journey 
When a draft map of the human 
genome was announced in 2000, 
followed by a complete map in 2003, 
breathless predictions of imminent 
breakthroughs blossomed 
everywhere from opaque scientific 
journals to the set of Oprah. If the 
expected clinical cornucopia has not 
yet materialized, other metrics show 
substantial results. The $3.8 billion 
the U.S. government invested in the 
Human Genome Project from 1988 
through 2003 helped spark $796 
billion in economic impact and $244 
billion in total personal income. In 
2010 alone, genomics research and 
industry activity directly and 
indirectly supported 310,000 jobs.4   
The result has been a surge in 
scientific discovery unparalleled in 
Western medicine.5 Consider: 
• More than 3,000 genes have been 
linked to Mendelian (single-
gene) disorders.6  
• Genome-wide association 
studies, searching beyond single-
gene disorders, have found 
significant correlations between 
more than 1,200 common genetic 
variations and 210 traits. These 
ranged from the clinically 
important (abdominal aortic 
aneurysm) to the curious (the 
ability to smell asparagus in 
one’s urine).7  
• Different genes code for different 
enzymes. One family of 
enzymes, cytochrome P450 
(CYP450), has been identified as 
involved in the metabolism of 90 
percent of all drugs.8 Just one 
member of this family, CYP2D6, 
is involved in the metabolism of 
100 different drugs, including 
analgesics, anti-arrhythmics, 
antidepressants, beta-blockers 
and opioid agents.9 
Genes, chromosomal abnormalities, 
proteins in the blood and similar 
indicators are called biomarkers, and 
they are the key to clinical genomics. 
For example, certain proteins are 
associated with more aggressive 
cancers, while other biomarkers can 
predict the response to a medication.   
In 2003, the FDA began asking 
companies to voluntarily submit 
some types of biomarker data related 
to clinical usage in order to enhance 
drug safety and effectiveness. In 
cases where having biomarker 
information is critical to safe and 
effective use, the FDA would not 
allow voluntary submission. The 
FDA also now requires drug 
companies to ensure that a 
companion diagnostic test is 
approved with the drug approval. 
As of June 30, 2011, the agency had 
approved genomic biomarker 
information for 76 unique drugs,10 
including the following: 
• Twenty-six different genetic 
biomarkers affecting 18 different 
therapeutic areas ranging from 
anti-infectives to psychiatry.  
• Common medications used to 
treat heart disease, depression 
and pain. 
• A preponderance of oncology 
drugs, with more to come: the 
oncology drug pipeline contains 
an estimated 300 Phase II or 
higher candidates with the 
potential for testing against a 
genetic biomarker.11  
 
Precision Labeling for “Precision Medicine” 
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Almost every cell in the human body contains two copies of the genome, with one each from the father and mother. (Egg and sperm 
cells contain only one genome copy, while red blood cells have none.) The genome itself is a kind of “book of life” composed of 23 
chapters (chromosomes), each containing a thousand or more stories (individual genes), and each of those stories is made up of 
base-pair DNA “words”—a total of nearly three billion of them.1 
Rather than being static, though, the genome is dynamic. Genetic code translates into a functional biological effect when the gene is 
“expressed” as a protein. When this happens, the underlying “genotype” (the total information in the genome) is actualized as a 
“phenotype” (the manifestation of an individual’s genome, including characteristics ranging from eye color to a disease state). 
A cause-and-effect relationship between a specific disease and a specific protein was first established by Linus Pauling and 
colleagues in a seminal 1949 paper on sickle cell anemia. Pauling confidently predicted “significant progress in the field of 
medicine as it is transformed from its present empirical form into the science of molecular medicine.”2 Six decades later, testing for 
sickle cell disease has improved, but there have been few advances in treating it. Despite the mapping of the human genome, there 
are three major reasons clinical progress has been so difficult.  
• There is much about the human genome that we still don’t know. There is roughly a 99.5 percent similarity between the 
genomes of any two human beings.3 These remaining differences amount to more than 16 million DNA variants, and 
although this number is tiny in relative terms, it is these variations that likely contribute to common diseases. Tests that 
sequence only a part of each genome may miss the bigger picture. Whole genome sequencing has great potential, but given 
the variation in human genomes, identifying a specific gene variant responsible for a particular condition remains extremely 
complex. 
• What a disease looks like in the exam room can be very different when seen from a genetic viewpoint. At a genetic level, 
the appearance of disease commonality can vanish. For instance, hypertrophic cardiomyopathy—a thickening of the heart 
muscle—looks like one disease on an echocardiogram, but 20 different genes could be involved. Even untangling complex 
genetic interactions may not yield much care improvement: “Type 2 diabetes is the most genetically understood and dissected 
disease out there,” notes James Evans, editor-in-chief of Genetics in Medicine. “Yet from a clinical standpoint, the [genetic] 
information is of questionable utility.”4 
• Environmental factors can actually change the way an individual’s genetic code is expressed. “Why Your DNA Isn’t Your 
Destiny,” is the way a January 18, 2010 Time magazine cover story summarized the impact of epigenetics. Environmental 
factors can alter the “epigenome” that sits on top of the genome and tells genes to switch on or off. Given the importance of 
diet and stress in epigenetics, the saying “you are what you eat” may be figuratively true at a molecular level. 
Put all this together and the genomic medicine challenge once thought to be like a jigsaw puzzle more closely resembles a Rubik’s 
cube. Eric Green and Mark Guyer of the National Human Genome Research Institute write, “Our ability to generate [genomic] 
information has outpaced our ability to analyze it.”5 
_____________ 
1 Ridley M. Genome: The Autobiography of a Species in 23 Chapters. New York: Perennial, 2000.  
2 Pauling L, Itano H, Singer SJ, et al. “Sickle Cell Anemia, a Molecular Disease.” Science, 110: 543–548, 1949. 
3 Levy S, Sutton G, Ng PC, et al. “The Diploid Genome Sequence of an Individual Human.” PLoS Biology, 5(10): e254, 2007. Note: Others have used a figure of 
99.9 percent similarity.  
4 Evans JP. “Health Care Professionals and Personalized Medicine.” (Paper presented at Personalized Medicine in the Clinic Conference, Phoenix, AZ, March 8, 
2010.) 
5 Green ED and Guyer MS. “Charting a Course for Genomic Medicine from Base Pairs to Bedside.” Nature 470: 204–213, 2011. 
 
 
The availability of genetic biomarker 
data on FDA-approved labels and 
information on diagnostic tests from 
organizations such as the National 
Institutes of Health (NIH) suggest an 
orderly process of translating 
research into patient care. The reality 
is far less systematic. 
Dissemination With and 
Without Validation  
Clinical genomics tests have carved 
out an increasingly important role in 
improving the quality of patient care. 
The tests are now used to make a 
prognosis, confirm a diagnosis, 
adjust a medication dose, make 
treatment decisions, and monitor 
therapy. However, two major barriers 
stand in the way of widespread use: 
proof of test validity and clinical 
utility. Test validity—whether a test 
accurately measures a biomarker—is 
an issue because current federal 
regulation only requires that these 
tests measure what they say they do, 
not whether what they purport to 
Genomic Science: Harder Than It First Looks 
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measure is of the clinical significance 
that is claimed. More broadly, the 
science underlying many studies of 
genetic biomarker significance has 
also been challenged.12 Proven 
clinical utility matters because 
physicians won’t use a test unless 
they believe it provides actionable 
information that can help patients.  
The FDA has generally exercised 
what it calls “enforcement 
discretion” in regard to so-called 
laboratory-developed tests (LDTs). 
In plain English, the FDA has 
decided not to regulate them. 
Historically, LDTs have been simple, 
well-understood tests designed by 
pathologists to enable the medical 
staff to diagnose rare conditions. 
Nicknamed “home brews,” they have 
a low risk of patient harm. At 
present, LDTs need only comply 
with the good manufacturing 
practices set out in the Clinical 
Laboratory Improvement 
Amendments (CLIA).13 CLIA 
requires that a lab show it is able to 
perform the test accurately, not that 
the test itself is valid. 
However, many of today’s diagnostic 
tests are as far from “home brews” as 
breakfast at a fast food franchise is 
from Mom’s homemade muffins. For 
example, in vitro diagnostic 
multivariate indexed assays 
(IVDMIAs) produced by commercial 
labs examine multiple genes and use 
complex algorithms to produce a risk 
score predicting prognosis for a 
disease or drug response. While test-
makers can voluntarily seek FDA 
approval, perhaps hoping for a 
marketing advantage, fewer than two 
dozen of more than a thousand 
genomic tests on the market have 
FDA approval.14  
Failing to Protect Patients from 
Harm 
In an April 2008 report by the 
Department of Health and Human 
Services, the Secretary’s Advisory 
Committee for Genetics, Health and 
Society recommended enhanced 
oversight of LDTs because of serious 
cost and quality concerns.15 One 
example was inaccurate test results 
intended to diagnose a serious 
genetic condition in some individuals 
with lower back pain. Opponents of 
more regulation, led by pathologists 
and clinical labs, warned that greater 
oversight could delay introduction of 
innovative new tests, and the FDA in 
June 2009 settled for publishing 
suggestions on how labs could 
voluntarily improve quality.16 
A year later, the agency altered 
course, citing “public health 
concerns” in a Federal Register 
notice that signaled an intent to 
regulate. “While the absence of FDA 
oversight may make it easier for 
laboratories to develop and offer tests 
on a rapid timeline…diagnostics 
critical for patient care may not be 
developed in a manner that provides 
a reasonable assurance of safety and 
effectiveness,” the agency wrote.17 
Indeed, a July 2010 article by the 
FDA commissioner and the NIH 
director added new problems caused 
by unreliable LDTs to the Secretary’s 
Advisory Committee’s list. The 
additional issues included: 
• Women falsely informed they 
were negative for the BRCA 
mutation, which conveys a high 
risk of breast cancer. 
• One woman whose ovaries were 
removed unnecessarily due to a 
false reading on an ovarian 
cancer test.  
• A test for Down syndrome that 
was discovered to be flawed just 
days before going to market.18  
At a March 2011 meeting sponsored 
by the National Comprehensive 
Cancer Network, one physician 
spoke of lung cancer patients 
routinely receiving “180 or 190” 
molecular tests despite a “lack of 
evidence” of the tests’ clinical 
validity.19 A few months later, a 
page-one article in the New York 
Times detailed how IVDMIAs from 
respected academic labs produced 
inaccurate treatment 
recommendations for cancer 
patients.20 As of mid-October 2011, 
the regulations promised in June 
2010 had not yet appeared. 
Separately, Senator Orrin Hatch (R-
UT) is reportedly preparing 
legislation on this issue. 
The Direct-to-Consumer Market 
Draws Attention 
The FDA, Congress and others have 
paid more attention to the much 
smaller, direct-to-consumer (DTC) 
genetic test market, where questions 
about accuracy and usefulness have 
generated national publicity and 
Congressional interest. DTC tests 
range from the well-established 
(paternity tests) to the pseudo-
scientific (predicting a child’s sports 
abilities) to the debatable (genome-
wide scans offering information on 
everything from ancestral origins to 
caffeine sensitivity to predisposition 
to various diseases. Supporters point 
to the tests’ personal utility, while 
skeptics refer to recreational 
genomics; the truth may depend on 
what test is used for what purpose. 
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The economic, clinical, legal and political questions swirling around testing for the BRCA mutations have involved all three 
branches of the federal government and numerous private players. It’s a story that displays both sides of the clinical genomics coin: 
personalized, predictive, preventive and precise medicine that can also be political, profit- and plaintiff-driven, and perplexing to 
both patients and professionals. The different actors involved are set forth in italics below. 
Women who inherit mutations in the Breast Cancer 1 and/or 2 (BRCA1 and BRCA2) genes have about a 50 percent lifetime risk of 
developing breast cancer and a 40 percent lifetime risk of ovarian cancer.1 Men with one or both mutations run an increased risk for 
prostate and even breast cancer. Both sexes have a higher risk of pancreatic cancer. 
The BRCA genes were cloned at the University of Utah in the early 1990s and quickly licensed to and patented by Myriad 
Genetics. An estimated 20 percent of the human genome is patented, and Myriad’s patents have been challenged in a long-running 
lawsuit pitting the American Civil Liberties Union, the Public Patent Foundation and the Association for Molecular Pathology 
against the U.S. Patent and Trademark Office, the University of Utah Research Foundation and Myriad. Myriad lost in a lower 
court in 2010, but the loss was partially reversed in July 2011 by a federal circuit court.2 That ruling, in turn, is being appealed to 
the U.S. Supreme Court. 
Deciding Who Gets the Test 
The financial stakes are high. Myriad sells its BRCAnalysis test for about $3,300 per patient, and it generates about $350 million in 
annual revenues. The U.S. Preventive Services Task Force (USPSTF) and the Centers for Disease Control and Prevention (CDC) 
both recommend BRCA testing only for those whose family history indicates increased risk. The USPSTF guidelines include seven 
different clinical scenarios, but only one in five primary care physicians could correctly identify what to do in all of them.3  
The absence of easy-to-use and reliable decision support is emblematic of the situation for less-publicized interventions. The 
Agency for Healthcare Research and Quality (AHRQ) commissioned research on a Web-based BRCA decision support tool for 
doctors and patients alike, but it had no money to fund full development. A tool that draws on the AHRQ work is being developed 
elsewhere drawing on federal funding for breast cancer awareness.  
Legal Issues 
In 2008 an Illinois appellate court ruled in a malpractice case4 involving BRCA testing that cost concerns are not a defense for 
recommending against a genetic test. That decision has led some analysts to worry that malpractice fears will prompt unneeded 
testing. A separate legal and ethical question is whether doctors with a BRCA-positive patient are obligated to contact non-patients 
who are that patient’s relatives.5  
Meanwhile, the one lawsuit filed in connection with the Genetic Information Nondiscrimination Act, passed in 2008 to protect 
individuals from actions by health insurers or employers, involved a BRCA-positive woman who allegedly lost her position at 
work after undergoing bilateral prophylactic mastectomy.6 
The BRCA Test in Context 
With all the attention paid to the BRCA mutations, it’s easy to forget that they occur in just two out of a thousand women in the 
general population and account for less than 5 percent of all breast cancers. To put those numbers into context, two hours per week 
of brisk walking can reduce the risk of breast cancer by nearly 20 percent for the 99.8 percent of women without the BRCA gene.7 
Perhaps the most important lesson, then, is that clinical genomics interventions should be seen as part of a larger picture. They are a 
means to an end. Appropriate use adds value and improves care; inappropriate use adds cost and can threaten health. 
_________ 
 
1 BRCA1 and BRCA2: Cancer Risk and Genetic Testing. Bethesda, MD: National Cancer Institute, 2009 www.cancer.gov/cancertopics/factsheet/Risk/BRCA. 
2 Pollack A. “Ruling Upholds Gene Patent on Cancer Test.” New York Times, July 29, 2011. 
3 Bellcross CA, Kolor K, Goddarfd KA, et al. “Awareness and Utilization of BRCA1/2 Testing Among U.S. Primary Care Physicians. American Journal of 
Preventive Medicine, 40(1): 61–6, January 2011.  
4 Downey v. Dunnington SIU. Appellate Court of Illinois, Fourth District, June 13, 2008, caselaw.findlaw.com/il-court-of-appeals/1411888.html. 
5 Surbone A. “Social and Ethical Implications of BRCA Testing. Annals of Oncology, 22(suppl 1): i60–i66, 2011. 
6 Lowe Z. “Woman’s Complaint Could Become Test Case for Genetic Discrimination.” Law.com, June 2, 2010, 
www.law.com/jsp/law/LawArticleFriendly.jsp?id=1202469829813. 
7 Breast Cancer. American Cancer Society, February 9, 2011, www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-risk-factors. 
  The BRCA Battle: Hope, Hype, Fear, Money, Politics and Science 
  
 Timely Analysis of Immediate Health Policy Issues    6 
 
A study of five companies selling 
genome-wide scans found they 
offered information on 213 
conditions, with 20 conditions (such 
as Alzheimer’s, heart disease, type 2 
diabetes, psoriasis and restless leg 
syndrome) having the greatest 
overlap.21 Different companies use 
different gene combinations and 
predictive algorithms. Predictions 
made by two of the most prominent 
companies about seven different 
diseases for five different individuals 
agreed less than half the time, one 
study found.22 A government report 
called DTC genetic tests “misleading 
and of little or no practical use to 
consumers.”23  
Supporters say the tests can motivate 
consumers to change behavior, 
although studies of the behavioral 
impact are equivocal at best.24 
Moreover, the tests’ uncertain 
accuracy also means some consumers 
will ask their doctor for unneeded 
additional testing or, conversely, 
falsely feel protected. In 2010, 
following publicity about plans to put 
a genomic test on drugstore shelves, 
the FDA reasserted its enforcement 
authority. So far, it has sent letters to 
27 DTC companies asking them to 
demonstrate that their claims meet 
legal standards.  
This regulatory boldness may have 
been helped by the fact that the DTC 
market accounts for less than $20 
million in total revenues25 and 
involves mainly small companies. By 
comparison, the larger molecular 
diagnostics market produces an 
estimated $6.2 billion in revenue for 
clinical laboratories, according to the 
research firm G2 Intelligence, and 
has grown rapidly from 14 percent of 
clinical lab revenues in 2006 to 21 
percent in 2009. 
 
A Lack of Data 
Unfortunately, the actual usage, cost 
and growth rate of clinical genomic 
tests are impossible to independently 
ascertain. That’s because individual 
genetic tests are not billed as separate 
items with the Current Procedural 
Terminology (CPT) codes used for 
insurance reimbursement. Instead, 
billing necessitates an idiosyncratic 
“code stacking” that obscures what 
was ordered. However, a sweeping 
update in CPT codes that takes effect 
in 2012 is expected to include more 
than 90 gene-specific and genomic 
procedures in the Tier 1 category of 
commonly performed tests, with 
additional codes to be added in 2013. 
The update will make it much easier 
for clinicians to order and be 
reimbursed for common genetic tests 
and will also generate data on usage. 
The most recent effort by researchers 
to even roughly estimate test usage 
seems to have been 15 years ago, 
when a mail survey completed by 
245 clinical labs reported 175,314 
genetic tests during 1996.26 
There is not even an accurate count 
of the number of genetic tests 
available to be billed for. The 
Secretary’s Advisory Committee 
endorsed a mandatory test registry at 
the same time it called for increased 
test regulation. The committee 
suggested that CDC, CMS or FDA 
might be an appropriate lead agency 
to manage the registry.27 More than 
three years later, a Genetic Testing 
Registry is set to be launched shortly; 
it will be voluntary rather than 
mandatory and will be managed by 
NIH, which will phase out its 
GeneTests site. Meanwhile, the 
Secretary’s Advisory Committee was 
itself phased out last year when its 
charter was not renewed. 
Registries notwithstanding, 
integrating clinical genomics into 
routine practice remains a 
challenging task. 
Putting Clinical Genomics 
into Practice 
Because clinical genomics can be 
complex and confusing, 
dissemination into patient care 
requires building an infrastructure 
that allows clinicians to appropriately 
order, use and be paid for tests and 
therapies. When a biomarker, a 
patient population that could be 
helped and the benefit itself are well-
defined, adoption is easier. Today, 
genetic testing routinely helps define 
therapeutic choices for some cancers 
(lung, colorectal, breast and 
leukemia), heart transplantation and a 
number of other conditions. In HIV 
disease, genetic testing to avoid a 
potentially life-threatening reaction 
to the drug abacavir has become the 
standard of care.  
Still, as one overview put it, “The 
number of genomic markers in 
clinical practice is very small. The 
number of markers to guide treatment 
decisions is even smaller.”28 There is 
an almost complete lack of evidence 
from traditional randomized 
controlled trials, forcing reliance on 
other forms of evidence. Over the 
past five years an estimated two 
dozen clinical genomics evidence 
reviews have been funded by 
agencies such as CDC, CMS and 
AHRQ (including through its 
USPSTF), yet very few have been 
able to unequivocally determine 
clinical utility, even for interventions 
that have made their way into 
practice.29  
Meanwhile, the funding for new 
research dwarfs the monies available 
to translate existing research into 
improved care. Consider the 
following examples: 
  
 Timely Analysis of Immediate Health Policy Issues    7 
 
• Less than 3 percent of genomics 
articles in the peer-reviewed 
literature between 2002 and 2006 
included information on 
translating research into 
practice.30  
• Just 1.8 percent of grants in 
cancer genetics for 2007 by the 
National Cancer Institute went to 
translational research, and a scant 
0.6 percent of publications on the 
topic dealt with translational 
issues.31  
• The federal office overseeing the 
Evaluation of Genomic 
Applications in Practice and 
Prevention (EGAPP) Working 
Group—a national effort to apply 
evidence-based medicine to 
genomics—recently had its 
budget cut by 90 percent. 
Funding for CDC’s Office of 
Public Health Genomics 
plummeted from $12.3 million in 
fiscal year 2010 to an expected 
$797,000 in fiscal year 2012.  
NIH recently announced plans for a 
National Center for Advancing 
Translational Sciences that includes 
genomic medicine, but its impact is 
unclear. In contrast, the influence of 
the private sector continues to grow. 
Contradictions and Confusion 
One of the most influential private-
sector voices is the Blue Cross and 
Blue Shield Association’s 
Technology Evaluation Center 
(TEC), whose recommendations go 
to health plans serving 100 million 
members. From 1997 through 2010, 
the TEC evaluated 24 genomic tests 
and therapies, including specific 
interventions and broad topics such 
as genetics in prostate cancer. About 
two-thirds of evaluations related to 
oncology.32 Large commercial 
insurers also review selected tests 
and drugs. 
It is not surprising that different 
groups reach different and even 
contradictory conclusions. In 2007, 
with much fanfare, the FDA 
approved a genetic test for sensitivity 
to warfarin, a commonly used and 
clinically important blood thinner. 
However, in 2009, CMS reviewed 
the science and professional group 
recommendations and decided 
Medicare would not cover the test’s 
use. On the other hand, even before 
testing for the KRAS mutation to 
guide colorectal cancer therapy was 
embraced by the FDA, some private 
payers decided to reimburse for it.33  
Another example involves breast 
cancer. The Blue Cross TEC 
determined that Oncotype Dx, one of 
two major genetic tests that can guide 
breast cancer therapy, met its 
evidence standards, but the similar 
MammaPrint test did not. Yet the 
MammaPrint test was FDA-
approved, while Oncotype Dx was 
never submitted for FDA approval. 
(As noted earlier, FDA approval is 
not required.) Meanwhile, CDC’s 
EGAPP Work Group concluded there 
was evidence for both tests, but not 
enough to make a recommendation.34 
Randomized trials are underway, but 
test usage continues to grow in the 
meantime. The company making 
Oncotype Dx says 50,000 patients 
got the test in 2009 at a retail cost of 
about $4,000 per patient.35  
A national survey of randomly 
selected primary care physicians 
found that 60 percent had ordered 
one of four common genetic tests, 
either for breast or colon cancer or 
for Huntington’s or sickle cell 
disease, and 74 percent had referred a 
patient for genetic testing.36 The 
latter two tests are for well-defined 
single-gene disorders. The former 
two tests, while widely used, have a 
less solid evidence base. Though 
patients expect their doctors to be 
able to explain the rationale and 
workings of genetic tests,37 they’re 
likely to be disappointed. While 98 
percent of physicians agree that 
genetic testing is useful in guiding 
drug therapy, just 10 percent feel 
adequately informed about using it.38 
Even where evidence is available, it 
has not been utilized.39 Patients and 
providers alike guess at which 
interventions are investigational and 
which are not. One large Blue Cross 
plan has posted its genomic medicine 
coverage policies online, but it is an 
exception.40 
As expensive anti-cancer medicines 
that provide substantial benefit to a 
small but genetically identifiable 
subpopulation become more 
common, the clinical and cost 
consequences of reimbursement 
decisions will rise. For instance, a 
recent study of a drug that targets the 
enzymes involved in blood clotting 
(apixaban) was hailed as “one of the 
most significant advances in 
cardiovascular medicine in the last 
five years” for its impact on mortality 
and complications.41 Yet when it 
comes to getting these types of 
medications into regular use, 
researchers recently concluded that 
“no medical literature exists 
suggesting how to formally integrate 
[pharmacogenomic] information into 
the formulary decision process” used 
by hospitals, medical groups and 
health plans.42  
Guidelines and Infrastructure 
Building 
One solution is to improve guideline 
development and dissemination to 
practitioners. Prominent efforts 
include those of the Clinical 
Pharmacogenetics Implementation 
Consortium, affiliated with NIH; the 
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American Society of Clinical 
Oncology; and the National 
Comprehensive Cancer Network. A 
few large health systems, such as 
Intermountain Health Care, are trying 
to build guidelines related to clinical 
genomics interventions into their 
electronic medical records (EMRs).  
A JAMA commentary called for the 
genomics community to reach out to 
clinicians with “unambiguous 
evidence that links the use of 
genomic information to improved 
patient-centered health outcomes, 
particularly for common 
conditions.”43 In the meantime, the 
for-profit sector is building its own 
implementation infrastructure: 
• McKesson, the giant 
pharmaceutical distributor, is 
creating electronic guidelines, 
billing codes and a database to 
track insurer payment policies. 
CVS-Caremark and Medco, two 
of the largest pharmacy benefit 
managers, are similarly involved 
in making it easier for providers 
to order and be paid for genetic 
interventions.  
• DNA Direct, a Medco 
subsidiary,44 provides a 
“turnkey” service to health plans 
and hospitals. There is a well-
defined menu of genetic tests, 
phone and Web-based advice for 
professionals and patients, and 
guidance on what actions to take 
based on test results.  
• Navigenics, with roots in DTC 
testing, is targeting primary care 
physicians in a partnership with 
national concierge medicine 
company MDVIP (a subsidiary 
of Procter & Gamble). 
Integrating genetic data into care 
management faces practical problems 
beyond guideline development and 
reimbursement. For instance, 
biomarker information in drug 
interaction databases provides value 
only if the patient’s genetic 
information is known. Kaiser 
Permanente and the University of 
California–San Francisco have 
genotyped 100,000 Northern 
California Kaiser enrollees under an 
NIH grant to link that data 
electronically to health surveys, other 
biological data and disease 
registries.45 (Kaiser is also part of a 
larger pharmacogenomics evaluation 
effort by the 15-member HMO 
Research Network.) The Department 
of Veterans Affairs recently 
announced the “Million Veteran 
Program,” an effort to consolidate 
genetic, military exposure, health and 
lifestyle information in a single 
database in order to study 
correlations between genetic 
variations and disease. 
Separately, a national collaborative 
led by the Coriell Institute for 
Medical Research is trying to 
determine whether patient-friendly 
genetic information, including 
genetic counseling, will lead 
individuals with chronic disease to 
change their behavior.46 Scalability 
may be an issue: there are only about 
2,000 certified genetic counselors in 
the nation.  
Integrating genetic data into an EMR 
for routine therapeutic use poses 
another challenge. Few systems have 
the capability to process or structure 
genetic data; even at academic 
medical centers, clinicians often must 
enter genetic data manually. 
Moreover, storage requirements for a 
patient’s entire genome will be orders 
of magnitude larger than traditional 
biomedical information. Experts 
estimate that just one genome could 
consume 370 GB, although the 
ability to focus on desired variants 
could shrink those requirements 
considerably.  
Genomic Therapy Goes Direct-to-
Consumer 
As with diagnostic tests, treatment 
options based on genetic test results 
have a direct-to-consumer (DTC) 
component that skirts traditional 
gatekeepers. The following are just a 
few examples: 
• PatientsLikeMe, a social media 
site, enables tracking of genetic 
variables, treatment choices and 
patient-reported outcomes for 
ALS.  
• Genomera, a start-up, plans to 
use “crowd-sourced health 
science” to enable patients to 
carry out genomic research. 
• Cancer Commons, an open-
science initiative, helps patients 
individualize treatment based on 
their tumor’s genomic subtype 
and then rapidly disseminate 
what they’ve learned to 
professionals and other patients.  
• N-of-One and other consultants 
offer to help patients find 
customized, genetic cancer-
fighting therapies.  
The extent to which these diverse 
activities will contribute to value-
enhancing use as opposed to just 
increasing volume and costs remains 
to be seen. The key is whether 
clinical genomics continues to be 
treated as a separate phenomenon or 
is recognized as one more 
technology, albeit a potentially 
extraordinary one, to be integrated 
into the health care system. 
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Race and ethnicity can complicate even ordinary clinical encounters; 
adding in genetics can make those conversations even more 
awkward. After all, it was not that long ago that genetic pseudo-
science was widely used to label some groups as intrinsically 
inferior.  
There are two separate issues involving race and ethnicity. The first 
is scientific: To what extent should clinical genomics guide treatment 
of different racial and ethnic groups? The second is economic: How 
should we ensure access by traditionally underserved racial and 
ethnic groups?  
The science is complicated by code words. A recent journal article 
referred to a study showing an increased risk of a potentially fatal 
adverse reaction in “Asian patients” taking carbamazepine, an 
anticonvulsant and mood stabilizer.1 The plain meaning refers to 
anyone from an Asian nation, but in the United States the word is 
used to refer to certain Asian subgroups. But genetic homogeneity is 
linked to geographically distinct populations and an ancestrally 
shared gene pool. “Asian” appearance can be misleading. The 
carbamazepine study was conducted in Taiwan with Han Chinese 
patients.2 Koreans, in contrast, tend to have the Alatic genetic 
makeup of the Mongolian region.  
Sometimes, research can help resolve the racial and ethnic jumble. 
The blood thinner warfarin is one of the most frequently prescribed 
drugs in the world, but too low or high a dose can have serious 
consequences. Three different groups—Whites, Blacks and East 
Asians—have different probabilities of genetic warfarin sensitivity. 
Without more information, these racial differences potentially 
complicate a dosing algorithm. However, an 11-nation study was 
able to identify a single VKORC1 polymorphism correlated to 
sensitivity across all racial groups, enabling one dosing algorithm for 
the drug.3 (Age, sex and vitamin K intake can also influence warfarin 
dose-response.)  
Sometimes, the way to avoid racial or ethnic concerns may be to 
screen everyone. For instance, a lawsuit that followed the death of a 
Black football player with sickle cell trait prompted the National 
Collegiate Athletic Association to recommend screening all Division 
I athletes for this condition. However, the universal screening 
remains controversial.4  
But sometimes there are simpler ways to deal with these complicated 
genetic scenarios. With sickle cell screening for athletes, for 
example, critics say the problem is not a genetic trait, but 
dangerously high-stress training methods. With both warfarin and 
carbamazepine, extra watchfulness for an adverse reaction 
immediately following the first dose can be just as effective as, and 
much less costly and complicated than, pre-dosage genetic testing.  
 
 
Uncomfortable Science 
Beyond the practical implications, individuals and ethnic groups may 
be uncomfortable with science that singles them out. The BRCA 
genes are more frequently found in Ashkenazi (Eastern European-
origin) Jews than in the general population, but Jewish groups remain 
uncomfortably aware that the false idea of a Jewish “race” has been a 
staple of anti-Semites. 
Many African Americans had similarly mixed feelings when in 2005 
the FDA approved BiDil, a combination of vasodilators to treat heart 
failure, as the first racially targeted drug. The idea of a race-based 
therapy was controversial,5 but in the case of BiDil the argument 
eventually became moot. The drug’s maker had tested it on self-
identified Black people, but not on any comparison population, in 
order to gain a new indication that would extend the drug’s patent 
life.6 BiDil was removed from the market in early 2008 after sales 
plummeted due to lower-priced generics. 
The conclusion that race-based drugs are only a marketing conceit, 
however, has also turned out to be premature. Recall that race and 
ethnicity can sometimes be a proxy for ancestral geography. Two 
recent papers in the journal Nature found a unique gene structure in 
African Americans. The researchers plan to pursue similar research 
with regard to Latinos, who have a mix of European, American 
Indian and African ancestry.7  
Scientific and socioeconomic concerns can overlap. For example, the 
Northwest-Alaska Pharmacogenomics Research Network is 
conducting pharmacogenomic research in American Indian, Alaska 
Native and rural Pacific Northwest populations with the aim of 
identifying genetic differences and also of ensuring that those 
populations have access to interventions based on those differences. 
Researchers have also noted ways in which discrimination and other 
environmental stresses among low-income populations can have 
epigenetic effects. 
Studies have examined the use of genetic testing by physicians 
serving primarily minority populations (who are significantly less 
likely to order a test),8 the use of BRCA testing by Hispanic and 
Black women at high risk (which has increased, but is still 
significantly lower than among non-Jewish White women),9 and the 
accuracy of a BRCA-carrier prediction tool among minorities (which 
generally works well for African Americans, Asian Americans and 
Hispanics, but has room for improvement with non-Hispanics).10 
Unfortunately, unfair profiling by race remains a danger in the brave 
new world of clinical genomics, and the old categories of haves and 
have-nots have not disappeared. As one study put it, “Access and 
knowledge barriers continue to limit the use of this technology to the 
wealthy, the well-insured and the medically well-informed.”11 
 
Race, Ethnicity and Genetics: A Difficult Mix 
_____________ 
1 The article referred to Stevens-Johnson syndrome among those taking carbamazepine. See Mrazek DA and Leerman C. “Facilitating Clinical Implementation of Pharmacogenomics.” Journal of the American Medical 
Association, 306(3): 304–305, 2011.  
2 Chen P, Lin JJ, Lu CS, et al. “Carbamazepine-Induced Toxic Effects and HLA-B*1502 Screening in Taiwan.” New England Journal of Medicine, 364(12): 1126–1133, 2011. 
3 Limdi NA, Wadelius M, Cavallari L, et al. “Warfarin Pharmacogenomics: A Single VKORC1 Polymorphism is Predictive of Dose Response Across 3 Racial Groups.” Blood, 115(18): 3827–3834, 2010. 
4 Koopmans J, Cox LA, Benjamin H, et al. “Sickle Cell Trait Screening in Athletes: Pediatricians’ Attitudes and Concerns.” Pediatrics, 128(3): 477-483, 2011. 
5 Carlson RJ. “The Case of BiDil: A Policy Commentary on Race and Genetics.” Health Affairs (Web Exclusive), October 2005. 
6 Wolinsky H. “Genomes, Race and Health.” EMBO Reports, 12(2): 107–109, February 2011.  
7 Brown E. “Scientists: New DNA Maps May Help Blacks’ Health.” Chicago Tribune. July 21, 2011, sec. 1, p. 17. 
8 Shields et al. 
9 Levy DE, Byfield SD, Comstock CB, et al. “Underutilization of BRCA 1/2 Testing to Guide Breast Cancer Treatment: Black and Hispanic Women Particularly at Risk.” Genetics in Medicine, 13(4): 349–355, 2011. 
10 Huo D, Senie RT, Daly M, et al. “Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic and Other Minority Families in the United States.” Journal of Clinical 
Oncology, 27(8): 1184–1190, 2009. 
11 Hall MJ and Olopade OI. “Disparities in Genetic Testing: Thinking Outside the BRCA Box.” Journal of Clinical Oncology, 24(14): 2197–2203, 2006. 
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The Promise of Clinical 
Genomics 
The buzz of excitement surrounding 
clinical genomics is similar in some 
ways to the early enthusiasm for 
computers in medicine. Both are 
technologies intuitively perceived to 
possess enormous power to change 
care for the better. Both have birthed 
snappy sound bites: “paper kills,” in 
the one case, or personalized, 
predictive, and precision medicine, in 
the other. And both have attracted 
true believers whose enthusiasm can 
sometimes lead them to blur the 
distinction between what is doable 
today and what might be possible 
tomorrow. As with health 
information technology, the rapid 
dissemination of clinical genomics 
technology is strongly backed by 
businesses that stand to reap 
significant profits from increased 
adoption. Although there is nothing 
inherently wrong with their 
advocacy, it should be recognized as 
such.  
Those similarities should sound a 
warning about realistic expectations. 
As the tools of DNA discovery enter 
mainstream medicine, clinical 
genomics is following the same path 
as other innovations: sometimes 
underused, because of a lack of 
understanding or reimbursement; 
sometimes appropriately used and 
reimbursed; sometimes overused or 
misused because of patient or 
provider enthusiasm, legal pressure 
or other factors; and sometimes used 
entirely appropriately to significantly 
improve patient care.  
The challenge is to ensure that as 
clinical genomics grows in 
importance, it meets the same 
evidence standards as other 
interventions. For example, clinical 
genomics advocates routinely assert 
that biomarker-guided therapy might 
eliminate expensive and harmful 
adverse drug reactions.47 However, 
were that proposition to be presented 
seriously to patient safety experts, 
there would be hard questions about 
the proportion of adverse reactions 
attributable to genetic causes in the 
first place, the type of patient data 
and information systems needed to 
implement this solution, and the 
probability that less costly and 
complicated interventions could 
accomplish at least as much a great 
deal more quickly. 
Policy Changes to Improve Value 
For policymakers, payers, providers 
and the public, the overarching 
imperative is for improved 
transparency of information. This 
includes: 
1. Data on evidence. A recent 
JAMA commentary noted “the 
thin line between hope and hype 
in biomarker research.”48 Right 
now, there are large gaps in 
knowledge, either because 
questionable studies or a lack of 
data entirely. Dissemination of 
information on genomics in 
practice is impeded by having 
information scattered across 
multiple websites. Government- 
and privately funded technology 
assessments often fail to 
coordinate methodologies and 
targets of inquiry. 
2. Data on implementation. NIH 
could demonstrate that its 
forthcoming Genetic Testing 
Registry will serve constituencies 
beyond clinical laboratories by 
making available comprehensive 
information to researchers and 
clinicians. The government could 
also fund more reliable research 
examining the benefits, harms 
and economic impact of genomic 
interventions in actual practice. 
At present, the medical literature 
is largely filled with anecdotes 
that provide little useful policy 
guidance.  
3. Data on regulatory actions. The 
FDA could finally regulate LDTs 
as promised, report on what LDT 
tests have been approved, and 
initiate post-marketing 
surveillance on their safety. FDA 
data on pharmacogenomic 
information available to 
prescribing physicians could also 
be examined, since the agency’s 
pronouncements on these issues 
can be contradictory and 
confusing.49 
4. Data for payment. Public and 
private payers could be clearer 
about what evidence they 
require. Medicare now pays for 
genomic interventions on the 
basis of ad hoc decisions. The 
Medicare Payment Advisory 
Commission could provide 
Congress with objective advice 
about how this technology should 
be implemented. Evidence-based 
criteria will become critical with 
the proliferation of expensive 
medications targeting small 
subgroups of patients, 
particularly those with cancer 
and other serious diseases. 
5. Data for consumers. Congress 
and federal agencies could give 
the public information and tools 
it needs to make good decisions 
about a technology that often 
raises uncomfortable ethical, 
clinical and economic questions. 
For instance, prenatal genetic 
testing is becoming easier and 
much less expensive, as is testing 
newborns for possible 
predisposition to a long list of 
diseases that may or may not be 
clinically relevant. Given the 
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risks and benefits of clinical 
genomic tests set forth in this 
paper, government and private 
payers alike could focus more 
closely on consumer education 
and protection.  
Developing the evidence base and 
educating doctors, patients and 
payers on how to use the evidence 
will take time, patience and money. 
The disbanding of a citizen advisory 
committee that consistently pushed 
the Department of Health and Human 
Services for greater oversight is 
disturbing. “Medicine is no longer 
able to simply adopt every new 
change or technology that comes 
down the pike,” says Robert Davis, a 
senior Kaiser Permanente researcher. 
“There is increasing awareness that 
things that are ‘obviously’ better… 
may have unanticipated costs and 
real medical harms that should make 
us all demand a higher level of 
evidence before we adopt change.”50   
As clinical genomics moves from 
bench to bedside and becomes a 
significant component of the U.S. 
health care system, it is advice well 
worth following. 
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